And while not as concrete, Human Genome Sciences and GSK have publicly stated that digital communications and social media will play a big role in launching Benlysta, a lupus drug in late-stage Phase 3. The companies hope to file with FDA in early 2010. According to a piece I read in Medical Marketing & Media, an exec at HGS confirmed that online will factor heavily into the marketing plan. “A lot of what advocacy groups do is through websites and other online forums. Patients organize themselves through social media. Through various kinds of online dissemination of information, we will put appropriate things out there.”